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Background: Schizophrenia is a highly heterogeneous disorder with positive and negative symptoms being
characteristic manifestations of the disease. While these two symptom domains are usually construed as distinct
and orthogonal, little is known about the longitudinal pattern of negative symptoms and their linkage with the
positive symptoms. This study assessed the temporal interplay between these two symptom domains and evaluated
whether the improvements in these symptoms were inversely correlated or independent with each other.
Methods: This post hoc analysis used data from a multicenter, randomized, open-label, 1-year pragmatic trial of
patients with schizophrenia spectrum disorder who were treated with first- and second-generation antipsychotics
in the usual clinical settings. Data from all treatment groups were pooled resulting in 399 patients with complete
data on both the negative and positive subscale scores from the Positive and Negative Syndrome Scale (PANSS).
Individual-based growth mixture modeling combined with interplay matrix was used to identify the latent trajectory
patterns in terms of both the negative and positive symptoms. Pearson correlation coefficients were calculated
to examine the relationship between the changes of these two symptom domains within each combined
trajectory pattern.
Results: We identified four distinct negative symptom trajectories and three positive symptom trajectories. The
trajectory matrix formed 11 combined trajectory patterns, which evidenced that negative and positive symptom
trajectories moved generally in parallel. Correlation coefficients for changes in negative and positive symptom
subscale scores were positive and statistically significant (P < 0.05). Overall, the combined trajectories indicated
three major distinct patterns: 1) dramatic and sustained early improvement in both negative and positive symptoms
(n = 70, 18%), 2) mild and sustained improvement in negative and positive symptoms (n = 237, 59%), and 3) no
improvement in either negative or positive symptoms (n = 82, 21%).
Conclusions: This study of symptom trajectories over 1 year shows that changes in negative and positive symptoms
were neither inversely nor independently related with each other. The positive association between these two
symptom domains supports the notion that different symptom domains in schizophrenia may depend on each
other through a unified upstream pathological disease process.
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It has been long recognized that schizophrenia is a highly
heterogeneous disease in terms of etiology, symptom
manifestation, and treatment response [1-3]. Data from
both randomized controlled trials [4-7] and a 30-year
long observational study [8] has shown that treatment
response is heterogeneous and is typically captured by
four or five trajectory groups with symptom severity
defined by the aggregated symptom scores. While the
core symptoms of schizophrenia are characterized by
positive (e.g., delusion, hallucination) and negative (e.g.,
emotional withdrawal) symptoms [9], it has been believed
that currently available antipsychotics work primarily on
relieving positive symptoms, whereas negative symptoms
are harder to treat [10-13]. The schizophrenia research
community has tremendous interest in understanding
the nature of negative symptoms [8,14,15].
The literature, though, is limited regarding the longitu-
dinal patterns of negative symptoms and their linkage
with the positive symptoms. Previous studies on the
relationship between negative and positive symptoms
have been mainly conceptually driven or cross-sectional
in nature [16]. It has been hypothesized that positive
symptoms are related to an increase in dopamine D2
activity, while blockade of the dopamine D2 receptors
may worsen negative symptoms, thus negative and
positive symptoms might be inversely correlated [17-19].
It was also hypothesized that these two domains of
symptomatology correspond to different etiopathogenic
and pathophysiological mechanisms [20,21]. Concurrently,
cross-sectional phenomenological studies have shown
that there was no significant relationship between
these two symptom domains, thus supporting the
notion that these two symptom domains may be or-
thogonal or independent with each other [16,22]. On
the other hand, hypotheses on the glutamatergic system
suggest that glutamate is involved in the mediation of
both positive and negative symptoms of schizophrenia
in the same direction, although the data are inferential
regarding drugs are currently in late stage clinical
development [23].
In this study, we utilized an individual-based trajec-
tory analysis technique to characterize the trajectories
of negative and positive symptoms and assessed the
temporal interplay between these two symptom do-
mains by using data from a 1-year schizophrenia trial
[24]. We seek to provide insight into the dynamic,
individual-level interaction between negative and positive
symptoms. Insight gained from these analyses could
aid in management of patients with schizophrenia by
raising awareness of the dynamic interplay between
these two characteristic symptom domains and may
help shed light on the pathological disease process of
schizophrenia.Methods
Study population
This analysis was based on data from a multicenter,
randomized, open-label, 1-year pragmatic trial studying
the cost-effectiveness of olanzapine as the first-line treat-
ment of schizophrenia in the United States. The method
and main results of this study have been published [24].
Study participants were recruited between 1998 and
2001 from both academic and community treatment
settings, primarily in mental health outpatient clinics.
Eligible patients were male and female, 18 years of age or
older, met Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria for schizo-
phrenia, schizoaffective disorder, or schizophreniform
disorder and met criteria for psychotic-symptom ex-
acerbation measured as a total Brief Psychiatric Rating
Scale score of at least 18; or had recently experienced
an adverse event (within 4 weeks with depo neuroleptic
therapy or within 6 days with oral neuroleptic therapy)
that was attributable to current antipsychotic treatment
and who are no longer tolerating treatment. Patients
with very serious, unstable physical illness and other
medical conditions or histories contraindicating use of
study drugs were excluded. Patients were randomized to
olanzapine, risperidone, or first-generation antipsychotics
(FGAs) at a 1:1:1 ratio. The study was designed to repre-
sent the usual clinical setting. Choice of the FGAs, initial
dosing, titration, and dosing adjustments were determined
by the treating physicians. Switching antipsychotic agents
was also allowed and was at the discretion of the treating
physician. Patients were assessed at seven visits, which
corresponded to weeks 0, 1, 3, 9, 21, 33, and 49. The
study protocol was approved by a central institutional
review board (IRB; Western IRB, 3535 7th Ave SW,
Olympia, WA 98502; Pr#: 980024) or by local IRBs,
and patients signed consent before entering the study.
For the current post hoc study, the null hypothesis
was that the improvement of negative and positive
symptoms is either inversely related or independent in
patients under antipsychotic treatment. Therefore, the
analysis was conducted using samples with complete 1-
year data on the Positive and Negative Syndrome Scale
(PANSS) negative subscale (N = 400) and the positive
subscale scores (N = 401), with an overall sample size of
399 patients with complete data on both subscales. Data
from different medication groups were pooled. Table 1
lists the patient demographics, diagnosis, baseline illness
characteristics, and symptom severity.Measures
The primary outcome measures of negative and positive
symptom severity levels were assessed at every study
visit using the PANSS negative and positive subscale
Table 1 Baseline patient characteristics
Variable Overalla
Age (years), mean (SD) 43.8 (12.0)
Male, n (%) 244 (61.2%)
Race/ethnicity, n (%)
Caucasian 236 (59.1%)
African American 118 (29.6%)
Other 45 (11.3%)
Currently employed, n (%) 84 (21.1%)
Inpatient setting at trial entry, n (%) 15 (3.8%)
Primary psychiatric diagnosis, n (%)
Schizophrenia 265 (66.4%)
Schizophreniform 3 (0.8%)
Schizoaffective disorder 131 (32.8%)
Age at first psychiatric hospitalization (years), mean (SD) 26.4 (9.4)
Number of previous episodes of schizophrenia, mean (SD) 6.4 (8.6)
Antipsychotic treatment in the past year, n (%)
Conventional(s) only 245 (61.4%)
Atypical(s) only 40 (10.0%)
Both 81 (20.3%)
Comorbid psychiatric diagnosis, n (%)
Mood disorder 86 (21.6%)
Anxiety disorder 19 (4.8%)
Psychoactive substance use disorder 150 (37.7%)
PANSS total score, mean (SD) 86.2 (19.7)
BPRS total score, mean (SD) 31.4 (11.5)
Abbreviations: BPRS Brief Psychiatric Rating Scale, PANSS Positive and Negative
Syndrome Scale, SD standard deviation.
an = 399 for age, gender, race/ethnicity, primary psychiatric diagnosis,
inpatient setting at trial entry, currently employed, antipsychotic treatment in
the past year, PANSS, and BPRS; n = 362 for age at first psychiatric
hospitalization; n = 392 for previous episodes of schizophrenia; n = 398 for
comorbid psychiatric diagnoses.
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item, clinician-rated instrument with each item scored in
an incremental seven-point severity scale (from 1 = absent,
2 =minimal, to up to 7 = extreme). The positive subscale
score is calculated as the sum of seven positive items,
and the negative subscale score is the sum of the seven
negative items. Thus, the negative and positive subscale
scores each range from 7 to 49. The PANSS was devel-
oped in the 1980s as a well operationalized instrument
that provides balanced representation of negative and
positive symptoms [25,26]. The psychometric properties
of PANSS had been studied and proved reliable and valid
[26,27]. The PANSS has been widely used in the research
of schizophrenia and is accepted by the Food and Drug
Administration as the primary efficacy outcome measure
for new drug applications treating schizophrenic spectrum
disorder [28-30].Statistical analyses
We used growth mixture modeling (GMM) [31] to model
PANSS negative and positive subscale scores. Growth
mixture modeling is an individual-based modeling tech-
nique that permits investigators to explore the longitu-
dinal features of disease progression (i.e., symptom
trajectories) and to cluster patients into latent classes
(subgroups) based on the differential symptom courses
[32]. GMM allows the assumption that there exist a
certain number of distinct pathways of growth or dis-
ease progression; therefore, subjects can be grouped
into a small number of distinct clusters based on their
disease progression profile [33]. The trajectory classes
are not defined a priori but are inferred from the data;
thus, the trajectory classes are also called latent classes.
Mathematically, GMM employs both categorical and
random-effect continuous latent variables to capture
population heterogeneity in the disease progression. The
categorical latent variables represent different trajectory
patterns (or classes), while the class-varying random-effect
continuous latent variables capture heterogeneity among
individuals within the class. For our study, we first applied
GMM on PANSS negative and positive subscale scores,
separately, using a series of models that included random
effects for intercept, linear slope, and quadratic slope.
Multiple statistical criteria (i.e., Bayesian information
criterion [BIC], sample-size-adjusted BIC [aBIC], and
bootstrap likelihood ratio test [BLRT]) were used to de-
termine the optimal number of latent trajectory classes.
Secondarily, we generated a matrix of PANSS negative
symptom trajectories versus positive symptom trajectories
to create patient groups based on the combined symptom
trajectories (e.g., if a patient falls into Class 1 for negative
symptom trajectories and Class 2 for positive symptom
trajectories, then the patient would belong to Group 1–2
of the combined symptom trajectories).
To further examine the relationship between negative
and positive symptoms, we calculated Pearson correlation
coefficients [34] between the changes in the two subscale
scores within each matrix cell by visit intervals after
randomization.
Results
Negative symptom trajectories
To identify the different trajectory subtypes in terms of
negative symptoms, data from 400 patients with complete
1-year PANSS negative subscale scores were fit to a
sequential series of quadratic growth models that
reflected one to five different trajectory latent classes.
The statistical indices associated with the series of
models (i.e., one to five latent classes) are shown in
Table 2. Per the aBIC (the lower, the better) and BLRT,
the four-trajectory model outperformed the other
models. Figure 1A shows the observed and estimated
Table 2 The fit statistics for the different GMM sequential models explored for negative symptoms
Number of classes 1 2 3 4 5
BIC 16518 16517 16522 16526 16548
aBIC 16467 16453 16445 16437 16446
BLRT N/A <0.001 <0.001 <0.001 0.167
Number of patients in each class 400 378/22 22/374/4 44/284/9/63 16/3/56/319/6
Abbreviations: GMM growth mixture modeling, BIC Bayesian information criterion, aBIC sample-size-adjusted Bayesian information criterion, BLRT bootstrap
likelihood ratio test, N/A not applicable.
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classes of the four-trajectory solution. There were 44, 284,
9, and 63 patients in each latent class, which represented
11%, 71%, 2%, and 16% of the entire cohort, respectively.
Although the smallest group accounts for only 2% of the
patients, its symptom profile is exclusive (i.e., a continuous
and robust response in PANSS negative subscale score
through the course of the study). Thus, we chose to
keep this distinct group and, as such, the four-trajectory
solution. Figure 1B shows the trajectory of the negative
symptom subscale for each patient in each latent class and
the observed mean trajectory of the corresponding latent
class. The mean trajectory of each class demonstrated a
reasonable level of concordance with individual patient
trajectories and provided straightforward evidence sup-
porting the four-trajectory solution.
Positive symptom trajectories
Likewise, we modeled a sequential series of quadratic
growth models for the positive symptoms with 401
patients who have complete data on the PANSS positive
subscale scores. The statistical indices associated with
the series of models (i.e., one to four latent trajectories)
are shown in Table 3. Per BIC, the three-trajectory model
outperformed the others. Although the BLRT showed a
significant difference of the four-class model versus
the three-class model (P < 0.001), the fourth class only
accounted for 1.5% (n = 6) of the patients and this fourth
class did not evidence a distinct symptom profile; thus,
the three-class model was chosen. With this three-class
model, the class sizes were of reasonable magnitude for
interpretation with 41 (10%), 317 (79%), and 43 (11%) of
patients in each latent class. In addition, the three-class
solution demonstrated a reasonable level of concordance
between each class mean trajectory and individual patient
trajectories within the class (Figure 2A and B).
Temporal interplay between negative and
positive symptoms
Figure 3 shows the negative and positive symptom tra-
jectory matrix. The four (negative symptom trajectory
classes) by three (positive symptom trajectory classes)
matrix formed 12 cells with one empty cell (cell 1–1, no
patient fell into this category), three cells (cells 3–1, 3–3,and 4–3) with only one patient each, one cell (cell 3–2)
with seven patients, and the remaining seven cells with
at least 14 patients each.
The trajectory matrix indicates that, within each matrix
cell (or patient groups), negative and positive symptom
trajectories tend to move in parallel over time (except in
two idiosyncratic individual cases of cells 3–1 and 4–3,
which account for two patients in total, 0.5% of the
studied population), while the negative symptom subscale
scores tend to be consistently higher than positive symp-
tom subscale scores (except cell 2–1, which accounts
for 20 patients, 5% of the studied population).
Pearson correlation coefficients between change in
PANSS negative and positive symptoms are shown in
Table 4 by visit interval within each of the seven matrix
cells, which contained at least 14 patients each. Positive
relationships were observed with 33 of the 35 studied
matrix cell by visit interval combinations. While the
two negative correlations (cell 4–2 at visit intervals
week 9–21 and week 21–33) were numerically small
and statistically non-significant, statistically significant,
moderate to large correlations were evidenced at some
visit intervals for each of the studied matrix cells.
Overall, the combined negative and positive symptom
trajectories suggested that 98% of the population generally
experienced one of three distinct patterns: 1) dramatic and
sustained early improvement (DSI) in both negative and
positive symptoms (cells 1–2, 1–3, and 2–3; n = 70, 18%);
2) mild and sustained improvement (MSI) in negative
and positive symptoms (cell 2–2; n = 237, 59%); or 3)
no improvement (NI) in either negative or positive
symptoms (cells 2–1, 4–1, and 4–2; n = 82, 21%). Two
percent of the patients followed idiosyncratic courses
(cells 3–1, 3–2, 3–3 and 4–3, n = 10).Discussion
This study employed an individual-based trajectory ana-
lysis method to study the temporal relationship between
negative and positive symptoms. We observed that negative
and positive symptom trajectories tended to move in
parallel over the 1-year study for most of the 11 patterns
of combined latent trajectory classes, and correlation
between the changes of PANSS negative and positive
Figure 1 Negative symptom trajectories. A: Estimated and observed mean curves. Triangles indicate estimated means, and circles indicate
observed means. B: Individual profiles by negative symptom trajectories. Light gray lines show trajectory of negative symptom subscale for each
patient in each latent class. Bold lines show observed mean trajectories of the corresponding latent classes.
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correlation coefficients. These findings suggest that changes
in negative and positive symptoms are neither inversely
related nor independent with each other, at least in
chronically ill patients treated in the United States,
who represent the study population.
To the authors’ knowledge, the present study is the
first to assess the differential symptom courses simul-
taneously using both negative and positive symptoms
over 1 year of antipsychotic treatment. The pattern (latent
trajectory classes) was mathematically derived using an
algorithm designed to group patients into clusters so that
the symptomatology pattern over 1 year is relatively
homogeneous in each class. There was no preconceivednotion (e.g., baseline characteristics) used to assign pa-
tients to one trajectory versus another. The adoption of
the trajectory analysis makes possible, for the first time,
the analyses and inspection of the relationship between
these two symptom domains taking into account both
the dynamic and heterogeneous nature of the symp-
tom manifestation [35,36]. In our previous research,
we applied trajectory analysis to schizophrenia clinical
trial data and identified subgroups of patients with
relatively homogeneous treatment-response patterns in
terms of the PANSS total score or positive symptom
subscale score [3,36,37], but this technique had yet
to be applied on negative and positive symptoms
simultaneously.
Table 3 The fit statistics for the different GMM sequential models explored for positive symptoms
Number of classes 1 2 3 4
BIC 16091 16066 16064 16070
aBIC 16040 16002 15988 15981
BLRT N/A <0.001 <0.001 <0.001
Number of patients in each class 401 42/359 41/317/43 39/94/262/6
Abbreviations: GMM growth mixture modeling, BIC Bayesian information criterion, aBIC sample-size-adjusted Bayesian information criterion, BLRT bootstrap
likelihood ratio test, N/A not applicable.
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negative and positive symptoms was not anticipated per
theories that these two sets of symptom domains might
be reversely correlated [19] or be independent with each
other [20,38]. Although the underlying mechanism of this
phenomenon is not well understood, our finding mightFigure 2 Positive symptom trajectories. A: Estimated and observed mea
observed means. B: Individual profiles by positive symptom trajectories. Lig
patient in each latent class. Bold lines show observed mean trajectories ofbe explained by the newly reconceptualized dopamine
hypothesis proposed by Howes and Kapur [39]. Based on
the emerging evidence in imaging, genetic, environmental,
phenotypic, and animal studies in the past two decades,
Howes and Kapur hypothesized that various symptoms
in schizophrenia are systematical manifestations of then curves. Triangles indicate estimated means, and circles indicate
ht gray lines show trajectory of positive symptom subscale for each
the corresponding latent classes.
Figure 3 Interplay matrix of negative and positive symptom trajectories. Abbreviations: DSI = dramatic and sustained early improvement,
MSI = mild and sustained improvement, NI = no improvement. The pink cells reflect DSI, the green cells reflect MSI, the gray cells reflect NI, and
the uncolored cells reflect idiosyncratic trajectories.
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mine dysregulation), and different symptom domains may
depend on each other through a unified upstream patho-
logical disease process [39]. Our findings that changes n
negative and positive symptoms were positively related may
be a reflection of a unified pathological disease process.
Furthermore, our findings corroborate those reported
by Addington and Addington [16] who studied 41 patients
with DSM III-diagnosed schizophrenia and assessed the
relationship between negative and positive symptoms
measured by the Scale for the Assessment of Negative
Symptoms and the Scale for the Assessment of the
Positive Symptoms. Their study found positive correlations
between these two symptom domains at both the acute
phase and remission phase and concluded that negative
and positive symptoms are not inversely related.Table 4 Pearson correlation coefficients between change in P
interplay matrix groups
Visit
interval
Group 1–2 Group 1–3 Group 2–1
(N = 29) (N = 14) (N = 20)
Week 1-3 0.65a 0.59a 0.60a
Week 3-9 0.36 0.61a 0.20
Week 9-21 0.69a 0.63a 0.32
Week 21-33 0.56a 0.47 0.42
Week 33-49 0.23 0.61a 0.42
aP < 0.05.We observed that negative and positive symptoms
moved in parallel over the 1-year period for most of the
11 patterns of combined latent trajectory classes. It could
be argued that the congruence of these two symptom
domains may be confounded by measurement error at
the level of rating (i.e., a high score on one dimension
leads to an erroneous high rating on another dimension;
therefore, as the score on one dimension improves the
score on the other dimension also seems to improve).
While the possibility of measurement error cannot be
ruled out in the context of an observational study, we
think it is rather unlikely in our study as the correlation
between the two dimensions was seen across time, and the
trajectory subgroups have been observed to be directionally
consistent with 1-year functional and health-related quality
of life outcomes in a follow-up analysis (data not shown).ANSS negative and positive symptom subscale scores by
Group 2–2 Group 2–3 Group 4–1 Group 4–2
(N = 237) (N = 27) (N = 19) (N = 43)
0.30a 0.02 0.41 0.58a
0.39a 0.39a 0.58a 0.35a
0.22a 0.11 0.62a −0.08
0.31a 0.54a 0.59a −0.19
0.36a 0.34 0.35 0.05
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between negative and positive symptom trajectories may
be a reflection of the secondary negative symptoms, the
effect on negative symptoms that associate with positive
symptoms, extrapyramidal side effects, or mood [40].
Again, we think the concept of secondary negative
symptoms is not likely to explain all the congruence
between these two symptom trajectories observed in
our study. Tollefson and Sanger [41] conducted a path
analysis to tease out the secondary effect of positive
symptoms, mood, or adverse events and found that nega-
tive symptoms of schizophrenia are directly responsive
to treatment. Stauffer et al. [42] studied primary nega-
tive symptoms using the proxy of predominant negative
symptoms precluding the effect of positive symptoms,
depressive symptoms, and parkinsonism, but the study
showed that such segregation of patients does not suggest
prognostic implications.
From a clinical perspective, negative symptoms, regard-
less of being primary or secondary in nature, as a whole
are an indication of disease severity [43] and are signifi-
cantly related to quality of life and level of functioning
[44,45]. Our findings agree with findings from a majority
of the studies on treatment with second-generation an-
tipsychotics in which both negative and positive symp-
toms improved at the population level [28-30,46-48].
Further, our findings suggest that, even at the individual
patient level, improvements in both negative and positive
symptoms are achievable, although there is still a con-
siderable unmet medical need in term of the magnitude
of the improvement in both the negative and positive
symptoms. The perception that negative symptoms do
not improve compared to positive symptoms may not
be totally accurate.
Moreover, we observed that negative symptom subscale
scores tended to be consistently higher than positive
symptom subscale scores. Although the clinical meaning
of a certain score on the PANSS negative or positive
subscale is not clear, this observation is consistent with
the previous findings that populations with chronic
schizophrenia have higher negative symptoms [45,49]
and if they improve in concert, it is understandable that
their severity will continue to be higher. Exceptionally,
one small group of 20 patients (5% of the overall studied
population) showed higher positive than negative symp-
tom subscale scores. It would be interesting to understand
the characteristics of such a group of patients in a larger
database.
Lastly, the data suggests that the majority of patients
generally experience one of the three distinct trajectory
patterns of treatment-response course: 1) dramatic and
sustained early improvement in both negative and posi-
tive symptoms, 2) mild and sustained improvement in
negative and positive symptoms, or 3) no improvementin either negative or positive symptoms. Further research
on the association between these treatment response
trajectory subgroups and the underlying determinants
(i.e., treatment choice, pathophysiology, and etiology
indicators) may help inform clinical practice or aid the
effort to develop targeted treatment of schizophrenia.
This study has a number of pertinent strengths and
limitations that warrant discussion. First, this study is
novel; the association between the two symptom domains
evidenced at the individual patient level and these analyses
have not been executed by others in this fashion. The field
has been accustomed to seeing data at the population
level (i.e., treatment group), an approach that does not
necessarily imply that negative and positive symptom
response is congruent. This study shows, however, at
the individual patient level, the two symptom domains
in fact do appear to display a commonality of response.
Second, results from this study would apply in real-world
practice settings. The data source is an open-label, 1-year,
pragmatic trial. The study sample included a heteroge-
neous patient population with a variety of comorbid
conditions, such as substance abuse; physicians were
allowed to adjust dosage or switch medications according
to their clinical discretion. Thus, the data reflect usual
clinical care.
On the other hand, the study is limited as a post hoc,
exploratory study. First, this study included patients who
were mostly chronically ill; therefore, the findings may
not be generalizable to patients in their early stage of the
illness. Second, the treatment was open-label and drug
switching was allowed. As such, we did not extend this
study to analysis and inference on the specific drug
effect, which is a clinically important question. Thirdly,
we recognize that the definition and construct of negative
and positive symptoms remains a subject of debate,
though PANSS negative and positive subscale scores
have been extensively used in schizophrenia clinical trials.
Lastly, this study was not able to differentiate primary
versus secondary negative symptoms due to the operational
complexity of the concept. We expect future studies
employing an advanced analytical method would help
shed light on this issue. Overall, replication of the finding
using independent data is necessary.
Conclusions
In summary, this study found that negative and positive
symptom trajectories move in parallel over time, and
changes in these two symptom domains are positively
correlated in patients undergoing antipsychotic treat-
ment. These findings support the Howes-Kapur hypoth-
esis that there may be a common upstream pathological
process that leads to different symptom manifestations in
schizophrenia.
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